Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01522417 · ClinicalTrials.gov registry record · Phase 2
Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention
A Phase 2 study, sponsored by Medicure.
- Completed
- Registry status
- Phase 2
- Development phase
- 535
- Enrollment target
NCT01522417: Completed Phase 2 study, sponsored by Medicure.
NCT01522417 is a Phase 2 study that has completed, run by Medicure. The registered enrollment target is 535 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (302% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01522417, a Phase 2 study, has completed, sponsored by Medicure.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 535 participants
- Enrollment target
Study Summary
The purpose this study is to assess whether a tirofiban regimen of a high-dose bolus plus a shortened infusion duration compared to label-dosing eptifibatide in patients undergoing percutaneous coronary intervention (PCI) is associated with a non-inferior composite rate of death, PCI-related myocardial infarction, urgent target vessel revascularization or in-hospital major bleeding within 48 hours following PCI or hospital discharge, whichever comes first.
Primary Outcome
The composite of death (any-cause), periprocedural myonecrosis (defined as ≥ 3 times the upper limit of normal troponin and at least 20% or greater than the baseline troponin value), urgent target revascularization (repeat PCI or any CABG procedure after the index PCI on a non-selective basis in the target vessel because of recurrent myocardial ischemia) or non-CABG related major bleeding as quantified according to REPLACE-2 bleeding criteria.
Interventions
- DRUG Eptifibatide
- DRUG Short Tirofiban
- DRUG Long Tirofiban
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 535 participants |
| Start Date | 2012-04 |
| Est. Completion | 2019-03 |
| Phase | Phase 2 |
What the finished NCT01522417 record still lists
NCT01522417 is an interventional study that assigns participants to a tested intervention. The registered 535 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (302% higher).
The record links to 0 conditions, and to 3 interventions - of which Eptifibatide is the first listed.
NCT01522417 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01522417 about?
NCT01522417 is a clinical study titled "Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention". The purpose this study is to assess whether a tirofiban regimen of a high-dose bolus plus a shortened infusion duration compared to label-dosing eptifibatide in patients undergoing percutaneous coronary intervention (PCI) is associated with a non-inferior composite rate of death, PCI-related myocard...
What is the current status of trial NCT01522417?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 535 participants. The study started on 2012-04. Estimated completion is 2019-03.
What interventions are being tested in trial NCT01522417?
The interventions under investigation include: Eptifibatide (DRUG), Short Tirofiban (DRUG), Long Tirofiban (DRUG).
Who is sponsoring clinical trial NCT01522417?
This trial is sponsored by Medicure, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01522417's enrollment target sits among peer trials
535 63rd of 2000 higher than 1,938 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05614739 · 535 participants · Phase 1
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
- NCT07091617 · 535 participants · NA
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
- NCT04910685 · 534 participants · Phase 2
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
- NCT06128551 · 534 participants · Phase 1
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia